Otsuka Pharmaceutical Co. Ltd., of Tokyo, reported top-line results from an additional phase III trial of tolvaptan in adults with autosomal dominant polycystic kidney disease (ADPKD), showing that patients treated with the selective V2 vasopressin receptor antagonist had a reduction in estimated glomerular filtration rate (eGFR) that was significantly less than in patients receiving placebo (p